Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 19 June 1998:
Vol. 280. no. 5371, pp. 1875 - 1880
DOI: 10.1126/science.280.5371.1875
Prev | Table of Contents | Next

Articles

Progress in the Development of an HIV-1 Vaccine

Norman L. Letvin

Containment of the acquired immunodeficiency syndrome (AIDS) epidemic will require an effective human immunodeficiency virus type 1 (HIV-1) vaccine. Accumulating evidence suggests that such a vaccine must efficiently elicit an HIV-1-specific cytotoxic T lymphocyte (CTL) response. Nonhuman primate models will continue to provide an important tool for assessing the extent of protective immunity induced by various immunization strategies. Although replication-competent AIDS viruses attenuated for pathogenicity by selective gene deletions have provided protective immunity in nonhuman primate models, the long-term safety of such vaccines in human populations is suspect. Inactivated virus and subunit vaccines have elicited neither CTLs nor antibodies capable of neutralizing a wide array of patient HIV-1 isolates. Considerable effort is now being focused on evaluating live vector-based vaccine and plasmid DNA vaccine approaches for preventing HIV-1 infection both in animal model and human studies. Our growing understanding of the biology of HIV-1 and immune responses to this virus will continue to suggest improved vaccination approaches for exploration.

The author is at Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. E-mail: nletvin{at}bidmc.harvard.edu

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
The Neutralization Properties of a HIV-Specific Antibody Are Markedly Altered by Glycosylation Events Outside the Antigen-Binding Domain.
L. R. Miranda, M. Duval, H. Doherty, M. S. Seaman, M. R. Posner, and L. A. Cavacini (2007)
J. Immunol. 178, 7132-7138
   Abstract »    Full Text »    PDF »
Screening for CD8 cytotoxic T lymphocytes specific for Gag of human immunodeficiency virus type 1 subtype B' Henan isolate from China and identification of novel epitopes restricted by the HLA-A2 and HLA-A11 alleles.
X. Gong, X. Gui, Y. Zhang, and P. Tien (2006)
J. Gen. Virol. 87, 151-158
   Abstract »    Full Text »    PDF »
HIV-1 Nef-induced FasL induction and bystander killing requires p38 MAPK activation.
K. Muthumani, A. Y. Choo, D. S. Hwang, A. Premkumar, N. S. Dayes, C. Harris, D. R. Green, S. A. Wadsworth, J. J. Siekierka, and D. B. Weiner (2005)
Blood 106, 2059-2068
   Abstract »    Full Text »    PDF »
Protection of Rhesus Monkeys against Infection with Minimally Pathogenic Simian-Human Immunodeficiency Virus: Correlations with Neutralizing Antibodies and Cytotoxic T Cells.
G. V. Quinnan Jr., X.-F. Yu, M. G. Lewis, P. F. Zhang, G. Sutter, P. Silvera, M. Dong, A. Choudhary, P. T. N. Sarkis, P. Bouma, et al. (2005)
J. Virol. 79, 3358-3369
   Abstract »    Full Text »    PDF »
HIV Vaccine Development in Asia.
J.-L. Excler (2003)
Journal of Health Management 5, 327-341
   Abstract »    PDF »
Mutagenic Stabilization and/or Disruption of a CD4-Bound State Reveals Distinct Conformations of the Human Immunodeficiency Virus Type 1 gp120 Envelope Glycoprotein.
S.-H. Xiang, P. D. Kwong, R. Gupta, C. D. Rizzuto, D. J. Casper, R. Wyatt, L. Wang, W. A. Hendrickson, M. L. Doyle, and J. Sodroski (2002)
J. Virol. 76, 9888-9899
   Abstract »    Full Text »    PDF »
Vaccination with Plasmid DNA Encoding TSA/LmSTI1 Leishmanial Fusion Proteins Confers Protection against Leishmania major Infection in Susceptible BALB/c Mice.
A. Campos-Neto, J. R. Webb, K. Greeson, R. N. Coler, Y. A. W. Skeiky, and S. G. Reed (2002)
Infect. Immun. 70, 2828-2836
   Abstract »    Full Text »    PDF »
Purification and Characterization of Oligomeric Envelope Glycoprotein from a Primary R5 Subtype B Human Immunodeficiency Virus.
I. K. Srivastava, L. Stamatatos, H. Legg, E. Kan, A. Fong, S. R. Coates, L. Leung, M. Wininger, J. J. Donnelly, J. B. Ulmer, et al. (2002)
J. Virol. 76, 2835-2847
   Abstract »    Full Text »    PDF »
Recombinant Canarypox Vaccine-Elicited CTL Specific for Dominant and Subdominant Simian Immunodeficiency Virus Epitopes in Rhesus Monkeys.
S. Santra, J. E. Schmitz, M. J. Kuroda, M. A. Lifton, C. E. Nickerson, C. I. Lord, R. Pal, G. Franchini, and N. L. Letvin (2002)
J. Immunol. 168, 1847-1853
   Abstract »    Full Text »    PDF »
A Variable Region 3 (V3) Mutation Determines a Global Neutralization Phenotype and CD4-Independent Infectivity of a Human Immunodeficiency Virus Type 1 Envelope Associated with a Broadly Cross-Reactive, Primary Virus-Neutralizing Antibody Response.
P. F. Zhang, P. Bouma, E. J. Park, J. B. Margolick, J. E. Robinson, S. Zolla-Pazner, M. N. Flora, and G. V. Quinnan Jr (2002)
J. Virol. 76, 644-655
   Abstract »    Full Text »    PDF »
Potent CD4+ T Cell Responses Elicited by a Bicistronic HIV-1 DNA Vaccine Expressing gp120 and GM-CSF.
D. H. Barouch, S. Santra, K. Tenner-Racz, P. Racz, M. J. Kuroda, J. E. Schmitz, S. S. Jackson, M. A. Lifton, D. C. Freed, H. C. Perry, et al. (2002)
J. Immunol. 168, 562-568
   Abstract »    Full Text »    PDF »
Plasmidic versus Insertional Cloning of Heterologous Genes in Mycobacterium bovis BCG: Impact on In Vivo Antigen Persistence and Immune Responses.
I. Mederle, I. Bourguin, D. Ensergueix, E. Badell, J. Moniz-Peireira, B. Gicquel, and N. Winter (2002)
Infect. Immun. 70, 303-314
   Abstract »    Full Text »    PDF »
Effects of Antigen and Genetic Adjuvants on Immune Responses to Human Immunodeficiency Virus DNA Vaccines in Mice.
A. C. Moore, W.-p. Kong, B. K. Chakrabarti, and G. J. Nabel (2002)
J. Virol. 76, 243-250
   Abstract »    Full Text »    PDF »
Fine Definition of the Epitope on the gp41 Glycoprotein of Human Immunodeficiency Virus Type 1 for the Neutralizing Monoclonal Antibody 2F5.
C. E. Parker, L. J. Deterding, C. Hager-Braun, J. M. Binley, N. Schulke, H. Katinger, J. P. Moore, and K. B. Tomer (2001)
J. Virol. 75, 10906-10911
   Abstract »    Full Text »    PDF »
Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection.
J. Pacanowski, S. Kahi, M. Baillet, P. Lebon, C. Deveau, C. Goujard, L. Meyer, E. Oksenhendler, M. Sinet, and A. Hosmalin (2001)
Blood 98, 3016-3021
   Abstract »    Full Text »    PDF »
A Commonly Recognized Simian Immunodeficiency Virus Nef Epitope Presented to Cytotoxic T Lymphocytes of Indian-Origin Rhesus Monkeys by the Prevalent Major Histocompatibility Complex Class I Allele Mamu-A*02.
S. Robinson, W. A. Charini, M. H. Newberg, M. J. Kuroda, C. I. Lord, and N. L. Letvin (2001)
J. Virol. 75, 10179-10186
   Abstract »    Full Text »    PDF »
Emergence and Kinetics of Simian Immunodeficiency Virus-Specific CD8+ T Cells in the Intestines of Macaques during Primary Infection.
R. S. Veazey, M.-C. Gauduin, K. G. Mansfield, I. C. Tham, J. D. Altman, J. D. Lifson, A. A. Lackner, and R. P. Johnson (2001)
J. Virol. 75, 10515-10519
   Abstract »    Full Text »    PDF »
Active Immunization in the United States: Developments over the Past Decade.
P. H. Dennehy (2001)
Clin. Microbiol. Rev. 14, 872-908
   Abstract »    Full Text »    PDF »
Identification of Human Immunodeficiency Virus Type 1 Subtype C Gag-, Tat-, Rev-, and Nef-Specific Elispot-Based Cytotoxic T-Lymphocyte Responses for AIDS Vaccine Design.
V. Novitsky, N. Rybak, M. F. McLane, P. Gilbert, P. Chigwedere, I. Klein, S. Gaolekwe, S. Y. Chang, T. Peter, I. Thior, et al. (2001)
J. Virol. 75, 9210-9228
   Abstract »    Full Text »    PDF »
Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity.
S. Sharpe, N. Polyanskaya, M. Dennis, G. Sutter, T. Hanke, V. Erfle, V. Hirsch, and M. Cranage (2001)
J. Gen. Virol. 82, 2215-2223
   Abstract »    Full Text »    PDF »
Induction of Neutralizing Antibodies and Gag-Specific Cellular Immune Responses to an R5 Primary Isolate of Human Immunodeficiency Virus Type 1 in Rhesus Macaques.
D. C. Montefiori, J. T. Safrit, S. L. Lydy, A. P. Barry, M. Bilska, H. T. T. Vo, M. Klein, J. Tartaglia, H. L. Robinson, and B. Rovinski (2001)
J. Virol. 75, 5879-5890
   Abstract »    Full Text »    PDF »
The flexibility of the TCR allows recognition of a large set of naturally occurring epitope variants by HIV-specific cytotoxic T lymphocytes.
F. Buseyne and Y. Riviere (2001)
Int. Immunol. 13, 941-950
   Abstract »    Full Text »    PDF »
Patient-Specific Cytotoxic T-Lymphocyte Cross-Recognition of Naturally Occurring Variants of a Human Immunodeficiency Virus Type 1 (HIV-1) p24gag Epitope by HIV-1-Infected Children.
F. Buseyne, M.-L. Chaix, C. Rouzioux, S. Blanche, and Y. Rivière (2001)
J. Virol. 75, 4941-4946
   Abstract »    Full Text »
HIV-specific effector cytotoxic T lymphocytes and HIV-producing cells colocalize in white pulps and germinal centers from infected patients.
A. Hosmalin, A. Samri, M.-J. Dumaurier, Y. Dudoit, E. Oksenhendler, M. Karmochkine, B. Autran, S. Wain-Hobson, and R. Cheynier (2001)
Blood 97, 2695-2701
   Abstract »    Full Text »    PDF »
Live attenuated HIV vaccines: Predicting the tradeoff between efficacy and safety.
S. M. Blower, K. Koelle, D. E. Kirschner, and J. Mills (2001)
PNAS 98, 3618-3623
   Abstract »    Full Text »    PDF »
Mature Dendritic Cells Infected with Canarypox Virus Elicit Strong Anti-Human Immunodeficiency Virus CD8+ and CD4+ T-Cell Responses from Chronically Infected Individuals.
J. Engelmayer, M. Larsson, A. Lee, M. Lee, W. I. Cox, R. M. Steinman, and N. Bhardwaj (2001)
J. Virol. 75, 2142-2153
   Abstract »    Full Text »
Prospects for Vaccines to Protect Against AIDS, Tuberculosis, and Malaria.
N. L. Letvin, B. R. Bloom, and S. L. Hoffman (2001)
JAMA 285, 606-611
   Abstract »    Full Text »    PDF »
Immunogenicity and Protective Efficacy of Oligomeric Human Immunodeficiency Virus Type 1 gp140.
P. L. Earl, W. Sugiura, D. C. Montefiori, C. C. Broder, S. A. Lee, C. Wild, J. Lifson, and B. Moss (2001)
J. Virol. 75, 645-653
   Abstract »    Full Text »
Evaluation of Cytotoxic T-Lymphocyte Responses in Human and Nonhuman Primate Subjects Infected with Human Immunodeficiency Virus Type 1 or Simian/Human Immunodeficiency Virus.
T.-M. Fu, D. C. Freed, W. L. Trigona, L. Guan, L. Zhu, R. Long, N. V. Persaud, K. Manson, S. Dubey, and J. W. Shiver (2001)
J. Virol. 75, 73-82
   Abstract »    Full Text »
In Vivo Attenuation of Simian Immunodeficiency Virus by Disruption of a Tyrosine-Dependent Sorting Signal in the Envelope Glycoprotein Cytoplasmic Tail.
P. N. Fultz, P. J. Vance, M. J. Endres, B. Tao, J. D. Dvorin, I. C. Davis, J. D. Lifson, D. C. Montefiori, M. Marsh, M. H. Malim, et al. (2001)
J. Virol. 75, 278-291
   Abstract »    Full Text »
Positive and Negative Aspects of the Human Immunodeficiency Virus Protease: Development of Inhibitors versus Its Role in AIDS Pathogenesis.
K. Ikuta, S. Suzuki, H. Horikoshi, T. Mukai, and R. B. Luftig (2000)
Microbiol. Mol. Biol. Rev. 64, 725-745
   Abstract »    Full Text »    PDF »
Glycoprotein Exchange Vectors Based on Vesicular Stomatitis Virus Allow Effective Boosting and Generation of Neutralizing Antibodies to a Primary Isolate of Human Immunodeficiency Virus Type 1.
N. F. Rose, A. Roberts, L. Buonocore, and J. K. Rose (2000)
J. Virol. 74, 10903-10910
   Abstract »    Full Text »
Dendritic Cells, Infected with Vesicular Stomatitis Virus-Pseudotyped HIV-1, Present Viral Antigens to CD4+ and CD8+ T Cells from HIV-1-Infected Individuals.
A. Granelli-Piperno, L. Zhong, P. Haslett, J. Jacobson, and R. M. Steinman (2000)
J. Immunol. 165, 6620-6626
   Abstract »    Full Text »    PDF »
Pathogenic Simian/Human Immunodeficiency Virus SHIVKU Inoculated into Immunized Macaques Caused Infection, but Virus Burdens Progressively Declined with Time.
P. S. Silverstein, G. A. Mackay, S. Mukherjee, Z. Li, M. Piatak Jr., J. D. Lifson, O. Narayan, and A. Kumar (2000)
J. Virol. 74, 10489-10497
   Abstract »    Full Text »
A Human Immunodeficiency Virus Prime-Boost Immunization Regimen in Humans Induces Antibodies That Show Interclade Cross-Reactivity and Neutralize Several X4-, R5-, and Dualtropic Clade B and C Primary Isolates.
F. Verrier, S. Burda, R. Belshe, A.-M. Duliege, J.-L. Excler, M. Klein, and S. Zolla-Pazner (2000)
J. Virol. 74, 10025-10033
   Abstract »    Full Text »
HIV Gag mRNA Transfection of Dendritic Cells (DC) Delivers Encoded Antigen to MHC Class I and II Molecules, Causes DC Maturation, and Induces a Potent Human In Vitro Primary Immune Response.
D. Weissman, H. Ni, D. Scales, A. Dude, J. Capodici, K. McGibney, A. Abdool, S. N. Isaacs, G. Cannon, and K. Kariko (2000)
J. Immunol. 165, 4710-4717
   Abstract »    Full Text »    PDF »
Simian Immunodeficiency Virus (SIV) gag DNA-Vaccinated Rhesus Monkeys Develop Secondary Cytotoxic T-Lymphocyte Responses and Control Viral Replication after Pathogenic SIV Infection.
M. A. Egan, W. A. Charini, M. J. Kuroda, J. E. Schmitz, P. Racz, K. Tenner-Racz, K. Manson, M. Wyand, M. A. Lifton, C. E. Nickerson, et al. (2000)
J. Virol. 74, 7485-7495
   Abstract »    Full Text »
Characterization of a Macaque Recombinant Monoclonal Antibody That Binds to a CD4-Induced Epitope and Neutralizes Simian Immunodeficiency Virus.
J. Glamann and V. M. Hirsch (2000)
J. Virol. 74, 7158-7163
   Abstract »    Full Text »
Genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T cell immunity.
Y. Lu, R. Friedman, N. Kushner, A. Doling, L. Thomas, N. Touzjian, M. Starnbach, and J. Lieberman (2000)
PNAS 97, 8027-8032
   Abstract »    Full Text »    PDF »
Immunization with a Modified Vaccinia Virus Expressing Simian Immunodeficiency Virus (SIV) Gag-Pol Primes for an Anamnestic Gag-Specific Cytotoxic T-Lymphocyte Response and Is Associated with Reduction of Viremia after SIV Challenge.
A. Seth, I. Ourmanov, J. E. Schmitz, M. J. Kuroda, M. A. Lifton, C. E. Nickerson, L. Wyatt, M. Carroll, B. Moss, D. Venzon, et al. (2000)
J. Virol. 74, 2502-2509
   Abstract »    Full Text »
Comparative Efficacy of Recombinant Modified Vaccinia Virus Ankara Expressing Simian Immunodeficiency Virus (SIV) Gag-Pol and/or Env in Macaques Challenged with Pathogenic SIV.
I. Ourmanov, C. R. Brown, B. Moss, M. Carroll, L. Wyatt, L. Pletneva, S. Goldstein, D. Venzon, and V. M. Hirsch (2000)
J. Virol. 74, 2740-2751
   Abstract »    Full Text »
Recombinant Modified Vaccinia Virus Ankara Expressing the Surface gp120 of Simian Immunodeficiency Virus (SIV) Primes for a Rapid Neutralizing Antibody Response to SIV Infection in Macaques.
I. Ourmanov, M. Bilska, V. M. Hirsch, and D. C. Montefiori (2000)
J. Virol. 74, 2960-2965
   Abstract »    Full Text »
Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization.
H. Wang, M. N. Griffiths, D. R. Burton, and P. Ghazal (2000)
PNAS 97, 847-852
   Abstract »    Full Text »    PDF »
A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits Is an Antigenic Mimic of the Trimeric Virion-Associated Structure.
J. M. Binley, R. W. Sanders, B. Clas, N. Schuelke, A. Master, Y. Guo, F. Kajumo, D. J. Anselma, P. J. Maddon, W. C. Olson, et al. (2000)
J. Virol. 74, 627-643
   Abstract »    Full Text »
Specific therapy regimes could lead to long-term immunological control of HIV.
D. Wodarz and M. A. Nowak (1999)
PNAS 96, 14464-14469
   Abstract »    Full Text »    PDF »
A Cell Line-Based Neutralization Assay for Primary Human Immunodeficiency Virus Type 1 Isolates That Use either the CCR5 or the CXCR4 Coreceptor.
A. Trkola, J. Matthews, C. Gordon, T. Ketas, and J. P. Moore (1999)
J. Virol. 73, 8966-8974
   Abstract »    Full Text »    PDF »
Role of Immune Responses against the Envelope and the Core Antigens of Simian Immunodeficiency Virus SIVmne in Protection against Homologous Cloned and Uncloned Virus Challenge in Macaques.
P. S. Polacino, V. Stallard, J. E. Klaniecki, S. Pennathur, D. C. Montefiori, A. J. Langlois, B. A. Richardson, W. R. Morton, R. E. Benveniste, and S.-L. Hu (1999)
J. Virol. 73, 8201-8215
   Abstract »    Full Text »    PDF »
Potent and Stable Attenuation of Live-HIV-1 by Gain of a Proteolysis-resistant Inhibitor of NF-kappa B (Ikappa B-alpha S32/36A) and the Implications for Vaccine Development.
I. Quinto, M. Mallardo, F. Baldassarre, G. Scala, G. Englund, and K.-T. Jeang (1999)
J. Biol. Chem. 274, 17567-17572
   Abstract »    Full Text »    PDF »
Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection.
X. J. Da Costa, C. A. Jones, and D. M. Knipe (1999)
PNAS 96, 6994-6998
   Abstract »    Full Text »    PDF »
Detection of Simian Immunodeficiency Virus Gag-Specific CD8+ T Lymphocytes in Semen of Chronically Infected Rhesus Monkeys by Cell Staining with a Tetrameric Major Histocompatibility Complex Class I-Peptide Complex.
H. L. Jordan, M. J. Kuroda, J. E. Schmitz, T. Steenbeke, M. A. Forman, and N. L. Letvin (1999)
J. Virol. 73, 4508-4512
   Abstract »    Full Text »
Distinct Pathogenic Sequela in Rhesus Macaques Infected with CCR5 or CXCR4 Utilizing SHIVs.
J. M. Harouse, A. Gettie, R. C. H. Tan, J. Blanchard, and C. Cheng-Mayer (1999)
Science 284, 816-819
   Abstract »    Full Text »
Linear Differentiation of Cytotoxic Effectors into Memory T Lymphocytes.
J. T. Opferman, B. T. Ober, and P. G. Ashton-Rickardt (1999)
Science 283, 1745-1748
   Abstract »    Full Text »
Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer.
A. Seth, I. Ourmanov, M. J. Kuroda, J. E. Schmitz, M. W. Carroll, L. S. Wyatt, B. Moss, M. A. Forman, V. M. Hirsch, and N. L. Letvin (1998)
PNAS 95, 10112-10116
   Abstract »    Full Text »    PDF »
Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys.
D. H. Barouch, A. Craiu, M. J. Kuroda, J. E. Schmitz, X. X. Zheng, S. Santra, J. D. Frost, G. R. Krivulka, M. A. Lifton, C. L. Crabbs, et al. (2000)
PNAS 97, 4192-4197
   Abstract »    Full Text »    PDF »
In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies.
G. Marzio, K. Verhoef, M. Vink, and B. Berkhout (2001)
PNAS 98, 6342-6347
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)